Executive team

Stijn Van Rompay

Stijn Van Rompay

CHIEF EXECUTIVE OFFICER, CO-FOUNDER AND ACTING CHIEF FINANCIAL OFFICER

Stijn co-founded and was the CEO of Alter Pharma, a high-growth pharmaceutical company focused on the development of complex generics and pharmacy-related product sales. He was also co-CEO of Uteron Pharma, a company focused on innovative female healthcare products.

Prior to these positions, Stijn was CFO and later, CEO of Docpharma (formerly quoted on Euronext Brussels) a generics and medical-device company. Under his leadership, the companies recorded strong growth and value creation. He also holds several non-executive director positions in the biotech sector, and acts as an advisor to venture capital investors. Stijn holds a Master’s degree in Applied Economics from the University of Antwerp.

Thomas Jacobsen

Thomas Jacobsen

CHIEF BUSINESS DEVELOPMENT OFFICER and CO-FOUNDER

He co-founded Alter Pharma, a pharmaceutical company focused on the development of complex generics and pharmacy-related product distribution. Prior to this, he worked with Docpharma, a generics and medical-device company that was acquired by Matrix Laboratories/Mylan Laboratories, where he worked on out-licensing of Docpharma’s products. Thomas started his career in the Scandinavian-based generics company Alternova, where he was responsible for licensing, product registration and launches. Thomas holds a Master’s Degree in Pharmacy from the University of Copenhagen and a Business Degree from Copenhagen Business School.
Koenraad Van der Elst

Koenraad Van der Elst

CHIEF LEGAL OFFICER

Koenraad served as General Counsel at Metris (currently Nikon Metrology), and acted as Secretary General & General Counsel of PUNCH INTERNATIONAL, a Belgian company listed on Euronext Brussels. He was also General Counsel & Secretary to the Board of PUNCH GRAPHIX plc, a company listed on the London Stock Exchange (AIM), and President of the Supervisory Board of PUNCH TECHNIX, a company listed on Euronext Amsterdam. Between 1995 and 2002, Koenraad was the Director of Legal Documentation at the Investment Banking Department (corporate finance & capital markets) of Generale Bank/Fortis Bank and was involved in most capital market transactions in Belgium (take-over bids, exchange offers, initial public offerings, etc.), as well as in a large number of corporate finance deals (M&A, advisory, fairness opinions, mergers, restructurings, etc.), at local, cross-border and international levels.

In addition, Koenraad was an assistant Professor at the University of Brussels (VUB) in Financial Law. He holds a law degree from the University of Brussels (VUB) and an MBA from EHSAL Brussels.

Dietmar Aichhorn

CHIEF OPERATING OFFICER

Over the course of his career at Sandoz, Mylan, Innovacell, ViraTherapeutics and Polpharma Biologics, Dietmar has held several senior management positions of increasing responsibilities including Head Clinical Development and Head Development. Dr. Dietmar Aichhorn is an expert in the fields of technical development, clinical development and regulatory affairs in the US, EU and other key geographies. Most recently, Dietmar had an assignment at Polpharma Biologics, where he was responsible for the clinical development of monoclonal antibodies, as well as overseeing all scientific affairs. Dietmar graduated as chemical engineer in Linz but has perfected his project management skills at the university of Vienna.
Marieke Vermeersch

Marieke Vermeersch

VP INVESTOR RELATIONS AND CORPORATE COMMUNICATIONS

Marieke has extensive industry-specific experience having spent 20 years in various senior roles with private and public life sciences companies, as well as investment banking. She has a proven track record of developing and implementing strategic communications and investor relations strategies. She was formerly responsible for investor relations, corporate communications, and business development at the leading Belgian biotech company Ablynx (acquired by Sanofi in 2018 for €3.9Bn), where she played a key role in institutionalizing and improving the Company’s IR and media relations efforts. Prior to that, she worked as buyside equity investment analyst for Degroof Petercam where she covered the European pharmaceutical, biotechnology and chemical sectors.  
Marieke holds a Master of Science degree in Bioengineering from the University of Gent and an MBA from Solvay Business School, Brussels.

Board of Directors

This subject will be soon available online

Any questions? Please contact us for all the answers you need!

If you have any enquiries about Hyloris, our mission, activities or any aspect of our company,
please click the link below to get in touch.

Contact Us